trust

SPECIALITIES

SPECIALIZED TREATMENTS

EXPERIENCE

16+ Yrs

LANGUAGES

English

PATIENTS

Helped 15000 patients

FEE

QUERY

$19.99

PHONE/VIDEO

$29.99

Recent Answers
Recent Answers

Professional Bio

Professional Bio

Dr.Jennifer Schwartz, MD, is triple board-certified in Internal medicine, Cardiology, and Cardiac electrophysiology. She graduated from the University of Michigan and New York University School of Medicine, and an Internship and residency in Internal Medicine at NYU Medical Center and Fellowships in cardiology and cardiac electrophysiology at New York-Presbyterian Hospital or Cornell Medical Center. She has been in practice since 2003 and has extensive research interests in sudden cardiac death, cardiac devices' MRI safety, and cardiac device programming for LVAD patients. She has taught staff, RNs, residents, and fellows. She has also been an invited speaker to many National Scientific Sessions (ACC, AHA, and HRS). Currently, she is practicing at Lahey Clinic, Burlington, United States.

Academics & Trainings

Academics & Trainings

Education

MD

New York University School Of Medicine

1996

Awards & Publications

Awards & Publications

Grants and Funding:

1) Scripps Clinical Research Development Award recipient. $50,000 award for a pilot project using Cardiac MRI to predict ICD discharges. Awarded November 2008.

2) Scripps Clinical Research Development Award recipient. $50,000 award for a pilot project investigating the risks of non-cardiac MRI in patients with pacemakers and ICDs. Awarded November 2009.

3) George Hewitt Foundation Clinical Research Fellowship. $62,000 stipend awarded for investigating the risks of non-cardiac MRI in patients with pacemakers and ICDs. Awarded January 2010.

Clinical Research:

1) Challenges and Outcomes of Posterior Wall Isolation for Ablation of Atrial Fibrillation. Kumar P, Bamimore AM, Schwartz JD, Chung EH, Gehi AK, Kiser AC, Hummel JP, Mounsey JP. J Am Heart Assoc. 2016 Sep 23:5(9).

2) Accuracy of patient perception of their prevailing rhythm: a comparative analysis of monitor data and questionnaire responses in patients with atrial fibrillation. Garimella RS, Chung EH, Mounsey JP, Schwartz JD, Pursell I, Gehi AK. Heart Rhythm. 2015 Apr;12(4):658-65.

3) Effect of left ventricular diastolic dysfunction on outcomes of atrial fibrillation ablation. Kumar P, Patel A, Mounsey JP, Chung EH, Schwartz JD, Pursell IW, Gehi AK. Am J Cardiol. 2014 Aug 1;114(3):407-11.

4) Effectiveness of atrial fibrillation monitor characteristics to predict severity of symptoms of atrial fibrillation. Patel N, Chung EH, Mounsey JP, Schwartz JD, Pursell I, Gehi AK. Am J Cardiol. 2014 May 15;113(10):1674-8.

5) Ventricular Tachycardia Events are Associated with Admissions for Infection or Heart failure in Patients with Left Ventricular Assist Devices and Implantable Cardio-Defibrillators. O’Neill TJ, Katz J, Waters S, Bowen A, Guise K, Chung E, Gehi A, Chang P, Jensen B, Mounsey JP, Schwartz J, AHA Abstract for 2013 Scientific Sessions.

6) A Novel Implantable Cardio-Defibrillator Programming Protocol for Patients with Left Ventricular Assist Devices Reduce Shocks. O’Neill TJ, Katz J, Waters S, Bowen A, Guise K, Chung E, Gehi A, Chang P, Jensen B, Mounsey JP, Schwartz J, AHA Abstract for 2013 Scientific Sessions.

7) Brugada-type patterns are easily observed in high precordial lead ECGs in collegiate athletes. Chung EH, McNeely DE 3rd, Gehi AK, Brickner T, Evans S, Pryski E, Waicus K, Stafford H, Mounsey JP, Schwartz JD, Huang S, Pursell I, Ciocca M. J Electrocardiol. 2013 Oct 1 [Epub ahead of print].

8) Why are clinically indicated, but lower risk patients less likely to receive ICD and CRT therapy? Mounsey JP, Schwartz J. J Am Coll Cardiol. 2013 Aug 23 [Epub ahead of print].

9) Use of a closed-loop irrigated catheter in epicardial ablation of ventricular tachycardia. Kumar P, Mounsey JP, Gehi AK, Schwartz JD, Chung EH. J Interv Card Electrophysiol. 2013 Apr 19.

10) Relation of atrial fibrillation burden and N-terminal pro-brain natriuretic peptide. Plitt DC, Chung EH, Mounsey JP, Schwartz JD, Pursell IW, Gehi AK. Am J Cardiol. 2013 May 1;111(9):208-12.

11) Effect of body mass index, physical activity, depression, and education attainment on high-sensitivity C-reactive protein in patients with atrial fibrillation. Rommel J, Simpson R, Mounsey JP, Chung E, Schwartz J, Pursell I, Gehi A. Am J Cardiol. 2013 Jan 15:111(2):208-12.

12) Hybrid epicardial-endocardial ablation using a pericardioscopic technique for the treatment of atrial fibrillation. Gehi AK, Mounsey JP, Pursell I, Landers M, Boyce K, Chung EH, Schwartz J, Walker TJ, Guise K, Kiser AC. Heart Rhythm. 2013 Jan:10(1):22-8.

13) Education attainment is associated with atrial fibrillation symptom severity. Goli NM, Thompson T, Sears SF, Mounsey JP, Chung E, Schwartz J, Wood K, Walker J, Guise K, Gehi AK. Pacing Clin Electrophysiol. 2012 Sep;35(9):1090-6.

14) Psychopathology and symptoms of atrial fibrillation: implication for therapy. Gehi AK, Sears S, Goli N, Walker TJ, Chung E, Schwartz J, Wood KA, Guise K, Mounsey JP. J Cardiovasc Electrophysiol. 2012 May:23(5):473-8.

15) “Virtual Research” May Point Towards Future Device Programming Trials. Cohen, J and Mounsey, JP, Journal of Cardiovascular Electrophysiology, March, 2011, 22(3):290-292.

16) Determining the Risks of MRI at 1.5 Tesla for Patients with Pacemakers and Implantable Cardioverter Defibrillator. Cohen, et al. Am J Cardiol. 2012 Dec 1:110(11):1631-6.

17) Pacemaker and Implantable Cardioverter Defibrillator Safety for Patients Undergoing Magnetic Resonance Imaging (The MagnaSafe Pilot Study). Cohen, et al., Oral abstract presentation, American College of Cardiology Scientific Sessions, Orlando, FL, March 2010.

18) Pacemaker and Implantable Cardioverter Defibrillator Safety for Patients Undergoing Magnetic Resonance Imaging. Cohen, et al., Abstract submission, American College of Cardiology Scientific Sessions, Orlando, FL, March 2009.

19) Cardiac Magnetic Resonance Imaging for the Preoperative Evaluation of Mitral Valve Disease. Cohen, et al., Abstract presentation, Society of Cardiovascular MRI Scientific Sessions, Orlando, FL, January 2009.

20) Pacemaker and Implantable Cardioverter Defibrillator Safety for Patients Undergoing Magnetic Resonance Imaging (The MagnaSafe Registry). Cohen, et al., Oral abstract presentation, American Heart Association Scientific Sessions, New Orleans, LA, November 2008.

21) Calcium Channel Blockers Influence the Sensitivity of T-Wave Alternans Testing in Patients with Ischemic Cardiomyopathy. Cohen, et al., Abstract presentation, American Heart Association Scientific Sessions, Chicago, IL, November 2002.

22) Do T-Wave Alternans and EP Testing Yield Complementary or Concordant Results? Stein, et al., Abstract presentation, American Heart Association Scientific Sessions, Chicago, IL, November 2002.

23) In Search of an Optimal Tilt Test Protocol. Mittal, et al., Abstract presentation, American Heart Association Scientific Sessions, Chicago, IL, November, 2002.

24) Beta-blockers Reduce the Sensitivity of T-Wave Alternans Testing in Patients with Coronary Artery Disease and Reduced Left Ventricular Function. Cohen, et al., Oral abstract presentation, North American Society of Pacing and Electrophysiology Annual Conference, San Diego, CA, May 2002.

25) Risk stratification in patients with non-ischemic cardiomyopathy: T-wave alternans vs. EP testing. Cohen, et al., Abstract Presentation, North American Society of Pacing and Electrophysiology Annual Conference, San Diego, CA, May 2002.

26) Does Adenosine Terminate Macroreentrant Atrial Tachycardia? Iwai, et al., Oral abstract presentation, North American Society of Pacing and Electrophysiology Annual Conference, San Diego, CA, May 2002.

27) Brugada-Like Repolarization Abnormalities Associated with Pheochromocytoma. Das, et al., Abstract Presentation, North American Society of Pacing and Electrophysiology Annual Conference, San Diego, CA, May 2002.

28) Left Bundle Branch Block Reduces the Specificity of T-Wave Alternans Testing. Cohen, et al., Abstract Presentation, American College of Cardiology Annual Conference, Atlanta, GA, March 2002.

29) Clinical Utility of an Adenosine-Nitroglycerin Tilt Test Protocol. Mittal, et al. Abstract Presentation, American College of Cardiology Annual Conference, Atlanta, GA, March 2002.

30) Does T-Wave Alternans Testing Predict Inducibility of Ventricular Tachycardia in Patients with Coronary Artery Disease and Depressed Left Ventricular Ejection Fractions? Cohen, et al., Abstract presentation, American College of Cardiology Annual Conference, Orlando, FL, March 2001.

31) Response to Adenosine Differentiates Focal From Macroreentrant Atrial Tachycardia: Validation Using Three-Dimensional Electroanatomic Mapping. Iwai, et al., Circulation 2002 106: 2793-2799.

32) Device therapies: new indications and future directions. Kumar P, Schwartz JD. Curr Cardiol Rev. 2015;11(1):33-41.

In-Person Consultation

Lahey Clinic

41 Burlington Mall Rd, Burlington, Ma, Zip: 01805, US